Healthcare
Valneva SE(INRLF)
Live Price
Offline$2.58
+0.00% today
1Y Change
-16.77%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $400.00M
- Revenue Growth
- +3.0%
- EPS Growth
- -630.4%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Valneva SE (INRLF) is a Healthcare stock with a market cap of $400.00M and listed on OTC. The stock last traded around $2.58 and down 16.8% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +3.0%, EPS growth of -630.4%, a dividend yield of 0.0%. What stands out right now is revenue +3.0%, EPS -630.4%, free cash flow +31.4% with operating margin -50.3% and ROIC -27.0%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines INRLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.0% vs +7.6% peer median
Operating Margin
Below sector median
-50.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 13, 2026 with an EPS surprise of -184.7% and a revenue surprise of -33.5%.
The operating picture looks softer than before
Revenue is at +3.0% and EPS is at -630.4%, with operating margin around -50.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | -184.7% | +0.0% | +0.0% | +0.0% |
2026 Mar 18, 2026 | -90.3% | +0.0% | -31.4% | -42.5% |
2025 Nov 20, 2025 | -105.2% | +0.0% | -3.2% | -3.0% |
Benchmark Edge
INRLF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INRLF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INRLF Max Drawdown
-60.83%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INRLF and SPY.
Company Overview
Valneva SE
Other OTC
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
- Leadership
- Thomas Lingelbach
- IPO Date
- Apr 23, 2010
- Employees
- 713
- Street Address
- 6 rue Alain Bombard
- Mailing
- Saint-Herblain, 44800
- Region
- Saint-Herblain, FR
- Reporting Currency
- USD
- Investor Line
- 33 2 28 07 37 10
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.3
- Price/Book
- 3.8
Growth
- Revenue
- +3.0%
- EPS
- -630.4%
- Free Cash Flow
- +31.4%
Profitability
- Gross Margin
- 38.7%
- Operating Margin
- -50.3%
- Net Margin
- -66.0%
- ROE
- -74.5%
- ROIC
- -27.0%
Balance Sheet
- Debt/Equity
- 1.95
- Current Ratio
- 2.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.